Correlation of reduced temporal muscle thickness and systemic muscle loss in newly diagnosed glioblastoma patients

Cecil ten Cate1 · Sandra M. H. Huijs2 · Anna C. H. Willemsen3,4,5 · Raphael C. O. S. Pasmans2 · Daniëlle B. P. Eekers6 · Catharina M. L. Zegers6 · Linda Ackermans7 · Jan Beckervordersandforth3,8 · Elisabeth P. M. van Raak9 · Monique H. M. E. Anten3,9 · Ann Hoeben3,5 · Alida A. Postma10 · Martinus P. G. Broen3,9

Received: 21 September 2022 / Accepted: 21 October 2022 / Published online: 17 November 2022 © The Author(s) 2022, corrected publications 2022, 2023

Abstract
Purpose Reduced temporal muscle thickness (TMT) has recently been postulated as a prognostic imaging marker and an objective tool to assess patients frailty in glioblastoma. Our aim is to investigate the correlation of TMT and systemic muscle loss to confirm that TMT is an adequate surrogate marker of sarcopenia in newly diagnosed glioblastoma patients.

Methods TMT was assessed on preoperative MR-images and skeletal muscle area (SMA) was assessed at the third lumbar vertebra on preoperative abdominal CT-scans. Previous published TMT sex-specific cut-off values were used to classify patients as ‘patient at risk of sarcopenia’ or ‘patient with normal muscle status’. Correlation between TMT and SMA was assessed using Spearman’s rank correlation coefficient.

Results Sixteen percent of the 245 included patients were identified as at risk of sarcopenia. The mean SMA of glioblastoma patients at risk of sarcopenia (124.3 cm², SD 30.8 cm²) was significantly lower than the mean SMA of patients with normal muscle status (146.3 cm², SD 31.1 cm², \( P < .001 \)). We found a moderate association between TMT and SMA in the patients with normal muscle status (Spearman’s rho 0.521, \( P < .001 \)), and a strong association in the patients at risk of sarcopenia (Spearman’s rho 0.678, \( P < .001 \)).

Conclusion Our results confirm the use of TMT as a surrogate marker of total body skeletal muscle mass in glioblastoma, especially in frail patients at risk of sarcopenia. TMT can be used to identify patients with muscle loss early in the disease process, which enables the implementation of adequate intervention strategies.

Keywords Temporal muscle thickness · Skeletal muscle area · Glioblastoma · Sarcopenia · Imaging marker
Introduction

Glioblastoma is the most common malignant primary brain cancer in adults. Current treatment consists of maximal surgical resection followed by a combination of radiation- and chemotherapy, achieving a median survival of only 15 months [1]. Patients’ frailty is a key factor negatively influencing survival, alongside with older age, less extensive tumor resection, corticosteroid treatment at baseline and the absence of promoter methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene [2]. Current widely used instruments to assess patients’ frailty, in terms of clinical condition, are the Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group (ECOG) Performance status. Although simple and useful, they are subject to bias, such as high interobserver variability [3].

The past 5 years, reduced temporal muscle thickness (TMT) has been studied as a potential prognostic imaging marker and objective tool to assess patients’ frailty in both recurrent as well as de novo glioblastoma patients. Some confirmed its prognostic value in newly diagnosed glioblastoma [4–9], whereas others rejected it [10–12]. In addition, some reported only a prognostic role in recurrent, but not newly diagnosed, glioblastoma patients [11, 13]. These varying results are probably due to the lack of established non-sex specific cutoff values, varying study sample size and high percentages of missing tumor data. Recently, in a hallmark study to overcome these problems and facilitate clinical implementation, Furtner et al. [8] classified glioblastoma patients as ‘at risk of sarcopenia’ or ‘with normal temporal muscle status’ based on sex-specific TMT cutoff values 2.5 standard deviation below a normative reference population, based on recommendations of the European Working Group on Sarcopenia in Older People (EWGSOP) [14, 15]. Patients at risk of sarcopenia had a significantly higher risk of a short time to progression (TTP) after finalizing first line multimodality treatment and death than patients with normal temporal muscle status [8]. Sarcopenia is a condition characterized by the loss of body skeletal muscle mass and function [16] and also a proven prognostic factor in several other, non-brain cancers [17–19]. Systemic muscle loss can be quantified by analysis of cross-sectional area of skeletal muscles at the level of the third lumbar vertebra (L3) on computed tomography (CT) scans, which currently is the preferred method in the majority of cancer studies [20]. Skeletal muscle area (SMA) at L3 is highly correlated with total body skeletal muscle mass and therefore used as a by proxy measurement of sarcopenia [21, 22]. Reduced TMT, however, reflects very specific local sarcopenia, and it is unknown if reduced TMT also reflects more widespread skeletal muscle loss throughout the body. Confirmation of such an association attributes to early detection of sarcopenia, enabling early development of preventative individualized exercise or nutritional strategies focused on muscle retention for glioblastoma patients at risk of sarcopenia.

Previous studies investigating TMT as a prognostic marker in glioblastoma patients postulate it as a surrogate marker for sarcopenia based on one single study. This study by Leitner et al. showed a high correlation between lumbar SMA and TMT [23]. Their study was conducted in a population of lung cancer and melanoma patients with brain metastasis in an advanced disease setting. Our purpose was to validate these findings, by investigating the correlation between reduced TMT and systemic muscle loss, defined as low lumbar SMA, in newly diagnosed glioblastoma patients. Doing so, we aim to confirm that TMT is an adequate surrogate marker for total body skeletal muscle mass in this specific population.

Methods

Patient selection

A Dutch multicentre retrospective study was performed at the Maastricht University Medical Center+ (MUMC+) and Zuyderland Medical Center (ZMC). From an existing genotyped glioma database covering routine clinical diagnostics, data from newly diagnosed glioblastoma patients diagnosed or treated in MUMC+ or ZMC between 2006 and 2020 were retrieved. Patients with glioblastoma (WHO grade 4), isocitrate dehydrogenase (IDH) wildtype, both MGMT hypermethylated or unmethylated were included. Patients with adequate preoperative brain Magnetic Resonance (MR) imaging as well as preoperative diagnostic abdominal CT scans were selected for this study. Patient characteristics and clinical data were collected from medical records as previously described [9].

Assessment of temporal muscle thickness

TMT measurements were performed on axial isotropic (1 × 1 × 1 mm) contrast-enhanced T1-weighted MR images, which were routinely performed for neurosurgery navigation on the same day or one day before surgery, as previously described [9]. In short: the MR plane was oriented parallel to the anterior commissure-posterior commissure line. TMT was measured in mm perpendicular to the long axis of the temporal muscle at the level of the Sylvian fissure (anterior-posterior hallmark) and the orbital roof (cranio-caudal landmark). The thickness was assessed on the left and right side separately. Then, TMT measurements of each side were summed and divided by two, resulting in a mean TMT per
patient. Based on the mean TMT sex-specific cut-off values from Furtner et al. [8], patients were classified as ‘patient at risk of sarcopenia’ (mean TMT ≤ 6.3 mm for men and ≤ 5.2 mm for women) or ‘patient with normal muscle status’ (mean TMT > 6.3 mm for men and > 5.2 mm for women).

Assessment of skeletal muscle area at the lumbar level

An estimation of body skeletal muscle mass composition was based on measurement of skeletal muscle area (SMA) in cm² at L3 on abdominal CT scans. For every patient, a single slice was manually selected from the pre-operative venous-phase CT scan on the level of L3 where both transverse processes were depicted. CT scans were assessed by one reviewer (CC) using Slice-O-Matic software v5.0 (Tomovision, Montreal, Canada) trained by a researcher with known prior experience with both the software as well as the SMA measurement (ACHW) [24]. Pre-established thresholds of Hounsfield units between −29 and 150 for skeletal muscle were used. The reviewer was blinded to patient characteristics and mean TMT values at the time of SMA assessment. Examples of TMT assessment on brain MR images and SMA assessment on CT scans at the level of the third lumbar vertebra are provided in Fig. 1.

Statistical analysis

Descriptive statistics were calculated for all patients. The statistical significance of differences between groups in mean TMT and in mean SMA was assessed using the Mann-Whitney U test. Correlation between mean TMT and SMA was assessed using Spearman’s rank correlation coefficient. A correlation coefficient of (−)0.8 to (−)1 was interpreted as a very strong association, of (−)0.6 to (−)0.8 as strong, of (−)0.4 to (−)0.6 as moderate, and of (−)0.2 to (−)0.4

Fig. 1 Examples of SMA assessment on transverse abdominal CT slices (A, B) and TMT assessment on axial T1-weighted contrast enhanced cranial MR images (C, D). A and C A 53 year old female at risk of sarcopenia according to TMT assessment (SMA = 76 cm²; TMT=3.4 mm). B and D A 63 year old female with normal muscle status according to TMT assessment (SMA =140 cm²; TMT=8.3 mm). Red: skeletal muscle; Yellow: visceral fat; Blue: subcutaneous fat
as a low association. There was no association for a correlation coefficient of 0 to (−)0.2. Statistical analysis was performed using IBM Statistical Package for the Social Sciences, version 25 (SPSS, Chicago, Illinois). A two-tailed P-value of <0.05 was considered statistically significant. In addition, SMA measurements of the total study population were compared with published data on a normative reference population [25].

Results

Cohort characteristics

The final study cohort consisted of 245 patients (Fig. 2). Their characteristics are listed in Table 1. Sex-specific mean TMT cutoff values were used to separate the cohort into patients at risk of sarcopenia (n = 39, 15.9%) and patients with normal muscle status (n = 206, 84.1%) [8].

Temporal muscle thickness

All patients had measurements for both right and left TMT. The mean TMT of all patients was 7.7 mm (SD 1.9 mm), with a mean TMT in the subgroups of patients at risk of sarcopenia and patients with normal muscle status of 5.0 mm (SD 0.9 mm) and 8.2 mm (SD 1.5 mm), respectively (P < .001). Male patients had a mean TMT of 8.3 mm (SD 1.7 mm) which was significantly higher than the mean TMT of 6.6 mm (SD 1.6 mm) in female patients (P < .001).

Table 1 Patient characteristics

| Variables                  | Study cohort (n=245) |
|----------------------------|---------------------|
| Gender                     |                     |
| Male, n (%)                | 156 (63.7)          |
| Female, n (%)              | 89 (36.3)           |
| Mean age at diagnosis, years (SD) | 64.6 (9.8)          |
| MGMT hypermethylation      |                     |
| Yes, n (%)                 | 96 (36.3)           |
| No, n (%)                  | 149 (63.7)          |
| At risk of sarcopenia*     |                     |
| Yes, n (%)                 | 39 (15.9)           |
| No, n (%)                  | 206 (84.1)          |

Sarcopenia at risk is defined as a TMT cutoff value of ≤ 6.3 mm for men and ≤ 5.2 mm for women, which is 2.5 SD below the mean TMT value of a normative reference population [8].

N number, SD standard deviation. MGMT O6-methylguanine-DNA methyltransferase

Skeletal muscle area at the lumbar level

The mean SMA of all patients was 142.8 cm² (SD 32.0 cm²). Female patients had a mean SMA of 110.7 cm² (SD 18.5 cm²), which was significantly lower than the mean SMA of 161.1 cm² (SD 22.1 cm²) in male patients (P < .001). The mean SMA of glioblastoma patients at risk of sarcopenia (124.3 cm², SD 30.8 cm²) was significantly lower than the mean SMA of patients with normal muscle status (146.3 cm², SD 31.1 cm², P < .001). We compared our SMA findings with reference values from a healthy population by using gender specific percentiles for skeletal muscle parameters [25]. The bar chart of the SMA distribution of our study population is compared with the reference population displayed as baseline normal distribution. Our studied population visually shows a relatively greater number of small SMA values at the lower percentiles compared to the normal reference population (Fig. 3).

Correlation TMT and abdominal muscle area

A scatterplot of the correlation between the mean TMT and SMA is shown in Supplementary Fig. 1. The Spearman correlation coefficient between mean TMT and SMA in the total study population is 0.537 (P = .000), representing a moderate correlation. By dividing the population in subgroups with ‘normal muscle status’ and ‘at risk of sarcopenia’ based on mean TMT cutoff values, we found also a moderate association in the normal muscle group (0.521, P < .001) but a highly significant strong correlation between SMA and TMT measurements in patients at risk of sarcopenia (0.678, P < .001).
Discussion

Our results confirm the use of TMT as a surrogate marker of total body skeletal muscle mass in glioblastoma patients at risk of sarcopenia. TMT can be used to identify patients with muscle loss early in the disease process, attributing to early detection of sarcopenia, enabling early development of preventative individualized intervention strategies for glioblastoma patients.

Only a few studies have investigated the correlation between TMT and SMA [23, 26, 27]. One study found a moderate correlation (r = .57) between TMT and psoas muscle area in trauma patients [26]. Although the correlation strength is comparable to our overall study population, there are some important differences. For example, Ranganathan et al. used CT imaging instead of standardized MR imaging to assess TMT values in a younger, non-cancer population [26]. Intriguingly, they found a stronger correlation in a more ‘frail’ subgroup, which is in line with our findings of a stronger correlation in glioblastoma patients in the ‘at risk of sarcopenia’ group, compared to the ‘normal muscle group’ based on TMT. This might indicate that especially in patients with lower muscle mass, the use of TMT as a surrogate marker of sarcopenia is most valid. Another study [27], found a strong correlation between TMT and calf circumference (0.608) and a moderate correlation with arm muscle circumference (0.433). However, TMT was assessed by ultrasound and only elderly (mean age 81 years) without malignancy were assessed, which is not representative for a population of glioblastoma patients. Only one study investigated the correlation between TMT and SMA in cancer patients [23]. Leitner et al. [23] analyzed the SMA at the level of the third lumbar vertebra and correlated these values with TMT on MR images of the brain in two cohorts of lung cancer (n = 93) and melanoma (n = 61) patients with brain metastases. They found a strong correlation between mean TMT and SMA (0.733) and concluded that TMT is a useful surrogate parameter for the estimation of skeletal muscle mass in patients with brain metastases. The strong correlation is comparable to the effect found in our subgroup of glioblastoma patients at risk of sarcopenia, but higher than the moderate correlation found in the normal muscle group. A possible explanation could lie in the fact that the study population of Leitner et al. already had an advanced stage of cancer at time of measurement, probably affected by several previous lines of treatment. In contrast, we assessed TMT and SMA at time of diagnosis, prior to surgery or any treatment. It is well known that cancer treatments and advanced disease stage contribute to muscle wasting. This is reflected by the lower mean SMA compared to our population (133 cm² vs 143 cm²). As mentioned before, correlation between TMT and SMA seems to be stronger in frail or patients at risk of sarcopenia, which probably substantiates the high correlation in the study of Leitner et al. [23].

We compared patients’ SMA at time of diagnosis with a representative healthy population. We found that already at diagnosis more patients than expected have lower SMA values (Fig. 3). Because of our retrospective study design,
we could not unravel if muscle loss at baseline is a con-
sequence of the disease symptoms (e.g. impaired mobility due
to paresis) or contrary a risk factor for the development of a
glioblastoma (e.g. frail patients are more prone to develop
an inflammatory process facilitating gliomagenesis [28, 29]).
In addition, it can also not be ruled out that the glioblas-
toma micro-environment plays a role in inducing systemic
inflammation facilitating sarcopenia. Although glioblastoma
is historically not considered a ‘systemic’ disease, evidence
of glioblastoma-derived mechanisms of, for example, sys-
temic immunosuppression is emerging in the past decade
[30]. Interestingly, skeletal muscle is postulated as potential
central link between sarcopenia and immune senescence in
elderly [31], which further supports the role of skeletal mus-

What the cause is, glioblastoma patients at risk of sar-
copenia have a higher risk of a short TTP after finalizing first
line multimodality treatment and death than patients with
normal muscle status, and also a higher risk of early dis-
continuation of treatment [9]. Glioblastoma patients might
benefit from targeting muscle loss early in the diagnostic or
treatment process. Interventions such as individualized exer-
cise programs or nutritional advises such as a protein-rich
diet [32], could reverse or stall the process of muscle wasting
and improve treatment completion and survival. In addition,
TMT might be used as an objective parameter of patients’
frailty, which can help physicians in dosing treatment or
considering patient inclusion in clinical trials. Prospective
studies are warranted to validate our findings and facilitate
implementation in daily practice.

Our study has limitations. First, SMA was assessed only
once by a single observer. To increase concordance CC was
trained by a researcher (ACHW) with proven experience in
SMA determination. The first 30 SMA assessments were
directly observed by the trainer and the remaining assess-
ments were checked at random [24]. In addition, we relied
on previously published data which showed an excellent
intra- and inter-observer agreement in determining SMA
on abdominal CT scans [33]. Second, we used only a single
abdominal slice (L3) as a surrogate marker of total skeletal
muscle mass. Although it is postulated that the L3 level is
the best by proxy measurement of skeletal muscle [34, 35], it
doesn’t account for body composition differences caused by,
for example ethnicity. However, we believe that the current
method provides a good estimation of skeletal muscle mass
with minimal effort and considerable accuracy. Developing
technologies, especially deep learning and machine learning
methods, will probably increase accuracy of muscle volume
estimations in the nearby feature. A third limitation is the
retrospective design, which made it not possible to investi-
gate muscular strength or biochemical markers such as sys-
temic inflammation known to affect muscle mass. Additional
longitudinal prospective studies are needed to confirm the

correlation between radiologic features with muscle func-
tion, which is a key feature of true sarcopenia. Additionally,
longitudinal studies will confirm if patients labeled at
risk of sarcopenia eventually develop sarcopenia throughout
the disease and treatment course. Fourth, 245 out of 328
patients had a preoperative abdominal CT scan. Imaging of
the abdomen is not incorporated in international guidelines
as a mandatory part of the diagnostic process of a presumed
primary brain tumor. However, at MUMC + and ZMC it is
common practice to perform abdominal and thoracic CT
imaging to rule out other causes, such as a brain metastasis
of a non-CNS- primary tumor, e.g. lung or breast cancer.
In case of clear radiologic features of a glioblastoma, e.g.
a butterfly glioma, no additional CT imaging is performed,
which explains why not all patients underwent CT imaging
preoperatively.

Conclusion

Our study confirms the use of TMT in newly diagnosed adult
glioblastoma patients as an adequate surrogate marker of
total body skeletal muscle mass. This correlation is espe-
cially strong for frail patients at risk of sarcopenia. Although
further prospective studies are needed, identifying these
patients early in the disease process might open up oppor-
tunities to implement exercise or nutritional strategies to
reverse or stall the process of muscle loss. Ultimately, this
hopefully improves the percentage of patients completing
treatment or receiving a second line treatment with improve-
ment of survival of this devastating disease.

**Supplementary Information** The online version contains supplemen-
tary material available at [https://doi.org/10.1007/s11060-022-04180-8](https://doi.org/10.1007/s11060-022-04180-8).

**Author contributions** MPGBroen, CtC, SMHH, ACHW, AAP contrib-
uted to the study conception and design. Data collection and analysis
were performed by CtC, SMHH, ACHW, EPMvR, AAP, MPGB. The
first draft of the manuscript was written by CtC and all authors com-
mented on previous versions of the manuscript. All authors read and
approved the final manuscript.

**Funding** This work was not funded.

**Declarations**

**Ethical approval** This study was approved by the institutional review
boards (reference number: METC2019-1396) of the participating cent-
ers and conducted in accordance with the Helsinki declaration and
national legislation.

**Open Access** This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long
as you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes
were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996

2. Gorlia T, van den Bent MJ, Hegi ME, Minnikanoff RO, Weller M, Cairncross JG et al (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981 – 22981/CE. Lancet Oncol 9(1):29–38

3. Kelly CM, Shahrokh A (2016) Moving beyond Karnofsky and ECOG performance status assessments with new technologies. J Oncol 6186543

4. An G, Ahn S, Park J-S, Jeun S-S, Hong Y-K (2021) Association between temporal muscle thickness and clinical outcomes in patients with newly diagnosed glioblastoma. J Cancer Res Clin Oncol 147(3):901–907

5. Liu F, Xing D, Zha Y, Wang L, Dong W, Li L et al (2020) Predictive value of temporal muscle thickness measurements on cranial magnetic resonance images in the prognosis of patients with primary glioblastoma. Front Neural 11(2):532392

6. Yan OY, Teng HB, Fu SN, Chen ZY, Liu F (2021) Temporal muscle thickness is an independent prognostic biomarker in patients with glioma: analysis of 261 cases. Cancer Manag Res 13:6621

7. Yesil Cinkir H, Colakoglu Er H (2020) Is temporal muscle thickness a survival predictor in newly diagnosed glioblastoma multiforme? Asia-Pac J Clin Oncol 16(5):e223–e27

8. Furtner J, Weller M, Weber M, Gorlia T, Nabors B, Reardon DA et al (2022) Temporal muscle thickness as a prognostic marker in patients with newly diagnosed glioblastoma: translational imaging analysis of the CENTRIC EORTC 26071–22072 and CORE Trials/TMT as prognostic marker in newly diagnosed glioblastoma. Clin Cancer Res 28(1):129–136

9. Broen MP, Beckers R, Willemsen AC, Huijs SM, Pasmans RC, Eekers DB et al (2022) Temporal muscle thickness as an independent prognostic imaging marker in newly diagnosed glioblastoma patients: a validation study. Neuro-oncology Adv 4(1):vdac038

10. Wende T, Kasper J, Prasse G, Glass Ä, Kriesen T, Freiman TM et al (2021) Newly diagnosed IDH-wildtype glioblastoma and temporal muscle mass: a multicenter analysis. Cancers (Basel) 13(22)

11. Huq S, Khalafallah AM, Ruiz-Cardozo MA, Botros D, Oliveira LA, Dux H et al (2021) A novel radiographic marker of sarcopenia with prognostic value in glioblastoma. Clin Neurol Neurosurg 207:106782

12. Muglia R, Simonelli M, Pessina F, Morenghi E, Navarrina P, Persico P et al (2021) Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis. Eur Radiol 31(6):4079–4086

13. Furtner J, Genbrugge E, Gorlia T, Bendszus M, Nowosielski M, Golfinopoulos V et al (2019) Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial. Neuro Oncol 21(12):1587–1594

14. Steindl A, Leitner J, Schwarz M, Nenning K-H, Asenbaum U, Mayer S et al (2020) Sarcopenia in neurological patients: standard values for temporal muscle thickness and muscle strength evaluation. J Clin Med 9(5):1272

15. Kennedy-Martin T, Curtis S, Fairies D, Robinson S, Johnston J (2015) A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials 16(1):1–14

16. Santilli V, Bernetti A, Mangone M, Paoloni M (2014) Clinical definition of sarcopenia. Clin cases mineral bone metabolism 11(3):177

17. Harimoto N, Shirabe K, Yamashita YI, Ikegami T, Yoshizumi T, Soejima Y et al (2013) Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg 100(11):1523–1530

18. Poutka SP, Carasasco A, Schmitt GD, Moynagh MR, Boorjian SA, Frank I et al (2014) Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer 120(18):2910–2918

19. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L et al (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9(7):629–635

20. Su H, Ruan J, Chen T, Lin E, Shi L (2019) CT-assessed sarcopenia is a predictive factor for both long-term and short-term outcomes in gastrointestinal oncology patients: a systematic review and meta-analysis. Cancer Imaging 19(1):1–15

21. Reiman T, Sawyer MB, Martin L et al (2008) Sarcopenia: a novel radiographic marker of sarcopenia in patients with newly diagnosed glioblastoma. J Neuro-Oncol 97(3):393–402

22. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR et al (1998) Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147(8):755–763

23. Leitner J, Pelster S, Schöpf V, Berghoff AS, Woitek R, Asenbaum U et al (2018) High correlation of temporal muscle thickness with lumbar skeletal muscle cross-sectional area in patients with brain metastases. PLoS ONE 13(11):e0207849

24. Degens JH, Dingemans AMC, Willemsen AC, Gietema HA, Harunks DM, Aerts JG et al (2021) The prognostic value of weight and body composition changes in patients with non-small-cell lung cancer treated with nivolumab. J Cachexia Sarcopenia Muscle 12(3):657–664

25. Van der Werf A, Langius J, De Van Der Schueren M, Nurmohamed S, Van Der Pant K, Blauwhoff-Buskermolen S et al (2018) Percentiles for skeletal muscle index, area and radiation attenuation based on computed tomography imaging acquired during routine care. Appl Physiol Nutr Metab 33(5):997–1006

26. Baeverfors H, Westerlund E, Nordling C, Thompson A, Almqvist L, Thulin M et al (2017) Sarcopenia as a predictor of adverse outcomes in glioblastoma patients undergoing standard-of-care treatment. J Neurooncol 130(3):417–425

27. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Boorjian SA et al (2014) Sarcopenia as a novel radiographic marker of sarcopenia in patients with newly diagnosed glioblastoma. J Neuro-Oncol 119(3):681–689

28. Koev I, Slavov E, Zhelyazkov H, Staikov D, Halacheva K, Sarafian V (2014) Multifocal glioblastoma multiforme, preceded by a
gemistocytic astrocytoma and dysregulated immune response. J IMAB 20(2):502–5
31. Nelke C, Dziewas R, Minnerup J, Meuth SG, Ruck T (2019) Skeletal muscle as potential central link between sarcopenia and immune senescence. EBioMedicine 49:381–388
32. BEAUDART C et al (2017) Current review of the SarQoL®: a health-related quality of life questionnaire specific to sarcopenia. Expert Rev PharmacoEcon Outcomes Res 17(4):335–341
33. van Vugt JL, Levolger S, Gharbharan A, Koek M, Niessen WJ, Burger JW et al (2017) A comparative study of software programmes for cross-sectional skeletal muscle and adipose tissue measurements on abdominal computed tomography scans of rectal cancer patients. J Cachexia Sarcopenia Muscle 8(2):285–297
34. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J et al (2004) Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985) 97(6):2333–2338
35. Thorning TK, Raziani F, Bendsen NT, Astrup A, Tholstrup T, Raben A (2015) Diets with high-fat cheese, high-fat meat, or carbohydrate on cardiovascular risk markers in overweight postmenopausal women: a randomized crossover trial. Am J Clin Nutr 102(3):573–581

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.